×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
When Can We Expect A Profit From Moberg Pharma AB (publ) (STO:MOB)?
Simply Wall Street
Moberg Pharma is bordering on breakeven, according to some Swedish Pharmaceuticals analysts. They expect the company to post a final loss in...
2 months ago
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year
Simply Wall Street
Key Insights Moberg Pharma to hold its Annual General Meeting on 14th of May Salary of kr1.99m is part of CEO Anna...
1 month ago
Reverse Split and Change of ISIN for Moberg Pharma AB (64/23)
Nasdaq
Referring to the bulletin from Moberg Pharma AB's annual general meeting, held on May 16, 2023, the company will carry out a reverse stock...
12 months ago
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely
Simply Wall Street
Moberg Pharma's cash burn of kr134m is about 60% of its kr225m market capitalisation. That's high expenditure relative to the value of the...
6 months ago
If You Had Bought Moberg Pharma (STO:MOB) Shares Five Years Ago You'd Have Made 151%
Yahoo Finance
But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. One great example is Moberg...
55 months ago
Cipher Pharma is a Buy, says Leede Jones Gable
Cantech Letter
Leede Jones Gable analyst Douglas W. Loe provided clients with an update on Cipher Pharmaceuticals on Wednesday and reiterated a “Buy”...
10 months ago
Moberg Pharma nails Asian foothold with flagship product
South China Morning Post
Swedish speciality pharmaceutical company Moberg Pharma has brought its flagship product, Kerasal Nail, to China, capitalising on the...
103 months ago
Moberg Pharma Sells OTC Business
Happi
Moberg Pharma Sells OTC Business ... In the most recent fiscal year, Kerasal Nail recorded its third consecutive year of double-digit growth in...
63 months ago
Moberg reports positive MOB-015 Phase II trial results in patients with onychomycosis
Clinical Trials Arena
Moberg Pharma has reported successful top-line results from a Phase II trial of MOB-015 to treat patients with onychomycosis (nail fungus).
116 months ago
Kerasal Nail issued US Patent, announced Moberg Pharma
European Pharmaceutical Review
Moberg Pharma have announced that the United States Patent and Trademark Office has issued a patent for Moberg Pharma's market-leading...
110 months ago